Since the majority of breast tumors are ER-dependent, blockade of E2 synthesis with aromatase inhibitors or antagonism of its action with anti-estrogens, represent first-line treatments for patients with ER-positive breast cancer. This evidence concerns the gene CYP19A1 and breast neoplasm.